Dyadic International, Inc. (Dyadic) a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bio-energy, industrial enzyme and biopharmaceutical industries, announced that it has been issued US Patent No. 7,923,236 entitled, “Fungal Enzymes” by the United States Patent and Trademark Office (USPTO).

The inventions embodied by this patent relate to the use of and methods for producing novel enzymes and their combinations to convert lignocellulosic biomass into fermentable sugars. These unique enzymes degrade lignocellulosic sugars including those that provide a synergistic release of sugars from plant biomass.

The inventions also relate to methods of using novel enzymes and their combinations in a variety of other processes including the simultaneous production of organic substances such as alcohol, ethanol, amino and organic acids as well as other organic substances. Additional claims are directed to a variety of pulp and paper manufacturing processes such as bio-refining, deinking and bleaching as well as for use in the treatment of waste streams and in textile and detergent processes. These enzymes were isolated from Dyadic’s patented and proprietary C1 fungus and additionally identified through the genome annotation project conducted by Dyadic in conjunction with Scripps Florida.

Dyadic’s president and CEO, Mark Emalfarb, stated, “This patent provides Dyadic with additional protection in the use of unique enzymes generated from Dyadic’s C1 platform technology to unlock the economic power of converting plentiful feed stocks of plant materials into sugars that can be fermented into chemicals, plastics, and fuels including ethanol, as a substitute for petroleum. These novel enzymes may also be applied in other industries in which Dyadic competes such as pulp and paper, waste treatment and textiles.”

This patent is the tenth US patent issued to Dyadic adding to its portfolio of 74 international patents and more than 33 pending patent applications worldwide which cover various features of Dyadic’s proprietary technologies.

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.